Drug
BI 2536 clinical trials
Also written BI 2536.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
11 studies that test it; most in 2006 (5)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 5 |
| 2007 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 1
Boehringer Ingelheim (10) · European Organisation for Research and Treatment of Cancer - EORTC (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BI 2536 is read from its arms, and is right about nine times in ten.
Testing it · 11
- Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical BenefitCompletedPhase 1Boehringer IngelheimNCT02211859Written as BI 2536
- Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)CompletedPhase 1Boehringer IngelheimNCT00243087Written as BI 2536
- BI 2536 Second Line Monotherapy in SCLCCompletedPhase 2Boehringer IngelheimNCT00412880Written as BI 2536
- Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung CancerCompletedPhase 2Boehringer IngelheimNCT00376623Written as BI 2536
- Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic CancerCompletedPhase 2Boehringer IngelheimNCT00710710Written as BI 2536
- Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic CancerTerminatedPhase 1Boehringer IngelheimNCT02215044Written as BI 2536, intravenous
- BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical BenefitCompletedPhase 1Boehringer IngelheimNCT02211872Written as BI 2536 BS, intravenous
- Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung CancerCompletedPhase 1Boehringer IngelheimNCT02211833Written as BI 2536
- BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid LeukaemiaCompletedPhase 2Boehringer IngelheimNCT00701766Written as BI 2536
- Phase II Study of BI 2536 in Prostate CancerCompletedPhase 2Boehringer IngelheimNCT00706498Written as BI 2536
- BI 2536 in Treating Patients With Recurrent or Metastatic Solid TumorsCompletedPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT00526149Written as BI 2536